10q10k10q10k.net
Silo Pharma, Inc.

Silo Pharma, Inc.SILOEarnings & Financial Report

Nasdaq

The Pharma Documentation Ring (P-D-R), founded in 1958, is a think tank of information and knowledge-management professionals representing major research-based pharmaceutical companies. The association has four aims:Promote exchange of knowledge among members Encourage commercial development of new information services and systems Jointly assess new and existing products and services Provide a forum for the information industry

SILO Q3 2025 Key Financial Metrics

Revenue

$18.0K

Gross Profit

$-2.7K

Operating Profit

$-1.2M

Net Profit

$-1.1M

Gross Margin

-14.8%

Operating Margin

-6388.2%

Net Margin

-6160.5%

YoY Growth

0.0%

EPS

$-0.12

Financial Flow

Silo Pharma, Inc. Q3 2025 Financial Summary

Silo Pharma, Inc. reported revenue of $18.0K for Q3 2025, with a net profit of $-1.1M (-6160.5% margin). Cost of goods sold was $20.7K, operating expenses totaled $1.1M.

Key Financial Metrics

Total Revenue$18.0K
Net Profit$-1.1M
Gross Margin-14.8%
Operating Margin-6388.2%
Report PeriodQ3 2025

Silo Pharma, Inc. Annual Revenue by Year

Silo Pharma, Inc. annual revenue history includes year-by-year totals (for example, 2024 revenue was $72.1K).

YearAnnual Revenue
2024$72.1K
2023$72.1K

Income Statement

Q4 2023Q1 2024Q2 2024Q3 2024Q4 2024Q1 2025Q2 2025Q3 2025
Revenue$18026$18026$18025$18025$18026$18026$18025$18025
YoY GrowthN/A0.0%0.0%0.0%0.0%0.0%0.0%0.0%

Balance Sheet

Q4 2023Q1 2024Q2 2024Q3 2024Q4 2024Q1 2025Q2 2025Q3 2025
Assets$7.7M$6.9M$8.0M$8.6M$7.4M$5.9M$6.7M$6.4M
Liabilities$1.6M$1.6M$2.1M$1.8M$2.4M$1.9M$1.7M$1.4M
Equity$6.2M$5.3M$6.0M$6.8M$5.0M$4.0M$4.9M$5.0M

Cash Flow

Q4 2023Q1 2024Q2 2024Q3 2024Q4 2024Q1 2025Q2 2025Q3 2025
Operating CF$-910012$-838179$-731803$-1.3M$-917432$-1.6M$-1.3M$-955493